Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Axitinib + PF-06801591 + SGN-TGT|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Axitinib||Inlyta||AG-013736|AG013736||KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 VEGFR Inhibitor (Pan) 36||Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).|
|PF-06801591||PF06801591|PF 06801591|Sasanlimab||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983).|
|SGN-TGT||SGN TGT|SEA-TGT|SGNTGT||TIGIT Antibody 19||SGN-TGT is a nonfucosylated monoclonal antibody that targets TIGIT, thereby preventing its interaction with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of an anti-tumor immune response (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT265).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04585815||Phase Ib/II||Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591||Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)||Active, not recruiting||USA | GBR | BEL | AUS||1|